Charles River extends gene therapy manufacturing alliance with NUS Medicine

Charles River Laboratories International, nd National University of Singapore’s NUS Yong Loo Lin School of Medicine NUS Medicine, a medical education institution with a world-renowned medical research field of stem cell biology and therapy, announced a High Quality HQ plasmid DNA development and manufacturing agreement. NUS Medicine will utilize Charles River’s market leading contract development and manufacturing organization CDMO expertise in HQ and GMP- compliant plasmid DNA, which serves as a critical starting material for its engineered stem cell cancer therapy and builds on a historic provision of research grade plasmid…”We are thrilled to continue our work with NUS Medicine and support their important work developing engineered stem cells for cancer therapy. Charles River has had decades of success manufacturing, and reliably delivering plasmid DNA as both a critical starting material and drug product, helping to safeguard our customer programs.” – Kerstin Dolph, Corporate Senior Vice President, Biologics Solutions, Charles River